Incoming BIO CEO Michelle McMurry-Heath (BIO)

BIO gets a new chief lob­by­ist to face off against the grow­ing ranks of crit­ics in Con­gress

BIO has se­lect­ed its next CEO to suc­ceed James Green­wood as one of biotech’s top lob­by­ists. And she comes with a dream ré­sumé that rings all the right bells — ex­cept for one.

She’s nev­er served in Con­gress as an elect­ed of­fi­cial.

Har­vard-ed­u­cat­ed with an MD from Duke, Michelle Mc­Mur­ry-Heath got the job af­ter spend­ing more than 5 years large­ly cen­tered on reg­u­la­to­ry work for J&J, spe­cial­iz­ing in de­vices. That gives her plen­ty of Big Phar­ma in­sight in­to the FDA that will help in in­flu­enc­ing a key gov­ern­ment agency. Even bet­ter, she jumped to in­dus­try from the FDA, where she was as­so­ciate di­rec­tor for sci­ence, cen­ter for de­vices and ra­di­o­log­i­cal health.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.